Joseph A. Sowell III - Jan 4, 2022 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Role
SVP; Chief Development Officer
Signature
/s/ Natalie Harrison Cline, Attorney-in-Fact
Stock symbol
HCA
Transactions as of
Jan 4, 2022
Transactions value $
-$7,702,662
Form type
4
Date filed
1/6/2022, 05:38 PM
Previous filing
Jan 3, 2022
Next filing
Feb 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCA Common Stock Sale -$5.75M -22.2K -64.24% $259.23 12.4K Jan 4, 2022 Direct F1, F2
transaction HCA Common Stock Options Exercise $1.12M +23.4K +189.16% $47.97* 35.7K Jan 5, 2022 Direct F1
transaction HCA Common Stock Tax liability -$3.07M -11.9K -33.17% $258.97 23.9K Jan 5, 2022 Direct F1
holding HCA Common Stock 21.3K Jan 4, 2022 By Trust (Reporting Person and Spouse, Trustees)
holding HCA Common Stock 8K Jan 4, 2022 By Trust (Reporting Person, Trustee)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCA Stock Appreciation Right Options Exercise $0 -23.4K -100% $0.00* 0 Jan 5, 2022 Common Stock 23.4K $47.97 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.00 to $259.79, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock appreciation rights vested at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the achievement of certain annual EBITDA performance targets.